ASCRS

Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis

A new event called SightLine and a series on adoption, implementation, integration (AII) draw the attention of ophthalmic administrators.

Abby Markward, MBA, executive director of the ASCRS Foundation and ASOA, discusses the foundation's global initiatives and the ASCRS Party for a Purpose.

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.

Recent sessions cast spotlight on emerging technologies and therapies.

Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.

Neda Nikpoor, MD, urges audience members to become more empowered in making small but meaningful, evidence-based changes in combating unconscious gender bias.

George O. Waring IV, MD, FACS, highlighted preliminary data from an open-label clinical trial, where his site was 1 of 4 in the US.

Deborah Gess Ristvedt, DO, shares highlights from her presentation and what these real-world cases mean for clinicians and their patients with glaucoma.

At this year's ASCRS meeting in Boston, Massachusetts, Shoham-Hazon, MD provided highlights from his two paper presentations.

At the 2024 ASCRS meeting, David M. Lubeck detailed highlights from his presentations on the minimally invasive glaucoma surgery (MIGS) space.

At this year's ASCRS meeting in Boston, Massachusetts, Josefina Botta, MD, MSc, discussed her real-world experiences with the RayOne EMV toric lens.

At this year's ASCRS meeting Rom Kandavel, MD, of Colvard-Kandavel Eye Center in Los Angeles, California discussed the paper he presented at the meeting, which focused on IOP lowering and medication burden for patients who received the iStent inject.

Adam Muzychuk, MD, BSc, FRCSC discusses his presentation, "Outcomes of an ultra-low cylinder powered (0.90) toric versus non-toric in low astigmatic patients undergoing cataract surgery."

At the 2024 ASCRS Greg Kunst, CEO of Aurion Biotech relayed the latest news from Aurion and the company's work in cell therapies for corneal endothelial disease.

At this year's ASCRS meeting in Boston, Massachusetts, Ophthalmology Times Europe caught up with Eris Jordan, OD talked about the big plans the Boston-based startup has for the year ahead. Watch the full video to find out what's in store for the company and its novel cell therapy in Japan, Canada and the United States in 2024.

At this year's ASCRS meeting, J. Morgan Micheletti, MD talked about myriad research projects he discussed at the meeting and also emphasized the importance of the Young Eye Surgeons (YES).

At this year's ASCRS meeting in Boston, Massachusetts, Pete England gave an update on ViaLase's development on the first femtosecond laser for the treatment of open-angle glaucoma.

At this year's ASCRS meeting in Boston, Massachusetts, Leonard Borrmann, CEO at Centricity Vision, about the company's new product ZEPTOLink, including first-in-human data.

Neda Nikpoor, MD, shares highlights from her presentation on the Light Adjustable Lens during an ASCRS symposia on IOL calculations.

Elizabeth Yeu, MD, discusses a case report for how the triple procedure can be beneficial for different patient populations in her ASCRS presentation, 'Human corneal endothelial cell transplantation combined with cataract extraction and PCIOL in subject with corneal edema.'

Paul Harasymowycz, MD, details his presentation "Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma" from this year's ASCRS meeting in Boston, Massachusetts.

William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.

Dan Tran, MD, shares key takeaways from his presentation, including a grading scale for incisions created with femtosecond laser.

OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive Surgery, while topline readout from the second Phase 3 OPTIMIZE-2 is anticipated later this year to support an NDA submission.

Rahul S Tonk, MD, MBA, sat down to discuss a roundtable discussion he had on DMEK and DSEK surgery at this year's ASCRS meeting held in Boston, Massachusetts, from Friday, April 5, to Monday, April 8, 2024.

Alejandro Espaillat, MD, sat down to discuss his presentation on pearls for the anterior segment surgeon at this year's ASCRS meeting held in Boston, Massachusetts.

Results of the study indicated that systemic treatment led to elevations in liver function test results, with some patients experiencing values twice as high as normal.

Contrary to the traditional understanding that this disorder remains stable, long-term structural changes were observed through spectral-domain optical coherence tomography (SD-OCT) imaging.

Investigators wanted to determine why patients who have retinal diseases such as diabetic retinopathy (DR) or age-related macular degeneration (AMD) can undergo cataract surgeries without experiencing a worsening of their retinal disease, while some patients do.